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Abstract: Antimicrobial compounds were synthesized by coupling 4-(4-
oxo-3,4-dihydroquinazolin-2-yl) butanoic acid with VP, GVP, VGVP and 
GVGVP peptides. Antimicrobial activities of the synthesized compounds 
were performed against various bacterial strains by disc diffusion method. 
The structure activity   relationship was evaluated with respect to 
hydrophobicity, polarity, chain length of peptides and alkyl chain length of 
quinazolinone. Correlations of analogs with respect to their antimicrobial 
activity in comparison with conventional drugs and probable mechanism for 
the activity were discussed.  
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Introduction 
In recent past pharmacological applications witnessed an unprecedented rate of the 
spread of microbes that are resistant to conventional antimicrobials worldwide. This 
poses a threat and the rapid emergence of resistant stains involve both gram-positive 
and gram-negative1. Efforts are currently underway to find new antimicrobials which act 
in a different mechanism of action against microbes and can potentially evade resistance 
provided by microbes. In order to achieve this in an efficient manner, it is important to 
understand the mechanism of action of these agents and the reason for their selectivity 
against microbes2. 
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 Antimicrobial peptides are found in most living organisms and have been most 
interesting compounds due to their structure and unique mode of action different from the 
most conventional antimicrobials3. These peptides exhibit activity against a broad spectrum 
of microbes but showed fairly low activity. Also several classes of antimicrobial peptides 
have been studied and their mechanisms of action against several microbes not yet clear and 
its elucidation would form a sound basis for the further development of new pharmaceutical 
compounds4. 
 Another class of compounds of interest in this scenario is quinazolinone alkaloids and 
its analogues5. These compounds extracted from natural sources were used as antimicrobials 
from long time. But recently mimicking of theses compounds with synthetic routes were 
found valuable route to find a new candidate as antimicrobials6. 
 In our earlier work, we have developed novel quinazolinone conjugated peptides by 
coupling peptides with 4-(4-oxo-3, 4-dihydroquinazolin-2-yl)propanoic acid (Precursor 1)7. 
The resulted compounds showed enhanced activity against both gram positive and gram 
negative bacterial strains compared to conventional antimicrobial viz., Streptomycin and 
tetracyclin. Further the activity depends on structural entities of the compounds; we were 
interested to extend the work by introducing the analogue of precursor 1 with mentioned 
peptides. The analogues were different from earlier compounds by elongating the alkyl 
chain as given in structures 2a-9a. These new chemical entities were synthesized by 
coupling mentioned peptides with 4-(4-oxo-3,4-dihydroquinazolin-2-yl) butanoic acid (1a) 
and evaluated for their antimicrobial  activities against various bacterial strains.  
Experimental 
All chemicals and reagents were obtained from Aldrich (USA), Spectrochem Pvt. Ltd 
(India) and Rankem Pvt. Ltd. (India) and were used without further purification. The amino 
acids used were L- series unless mentioned. The 1H NMR, mass and HPLC spectra were 
recorded on 300 MHz Bruker FT-NMR Spectrometer, LCMSD-Trap-XCT instrument and 
Agilent-1100 HPLC respectively. The bacterial strains used were obtained from department 
of Studies in Biotechnology, University of Mysore, India, namely, Bacillus substilis, 
Escherichia coli, Pseudomonas fluorescens, Xanthomonas campestris pvs and Xanthomonas 
oryzae.  
Synthesis  
The 4-(4-oxo-3,4-dihydroquinazolin-2-yl)butanoic acid (1a) was synthesized as previously 
reported using anthranilide and pentanedioic acid anhydride7,8. The peptides were 
synthesized by stepwise solution phase method using Boc chemistry. The Boc group was 
used for temporary Nα-protection and its removal was achieved with TFA. The resulting 
peptides were coupled with 1a as shown in the Scheme 1. The carboxyl group was protected 
by benzyl ester and its removal was effected by hydrogenolysis using HCO2NH4 as 
hydrogen donor and 10% Pd-C on carbon as catalyst, described by our earlier method7. The  
series of compounds 2a, 4a, 6a, 8a possess precursor 1a coupled with benzyl esters of VP,  
GVP, VGVP and GVGVP peptides and compounds 3a, 5a, 7a, 9a were their hydrolyzed  
products  respectively. 
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General procedure for the synthesis of 4-(4-oxo-3,4-dihydroquinazolin-2-







(i) EDCl/HOBt and DIEA,(ii) HCO2NH4/10% Pd-C 
Scheme 1. Synthesis of heterocyclic conjugated peptides.   
The coupling of 4-(4-oxo-3,4-dihydroquinazolin-2-yl)butanoic acid with benzyl 
esters of peptides 
To the stirred solution of 4-(4-oxo-3,4-dihydroquinazolin-2-yl)butanoic acid (0.2 g, 0.86 mmol) 
in  DMF (5.0 mL) cooled to 0C with crushed ice, added TFA.VP-OBzl (0.36 g, 0.86 mmol), 
DIEA (0.61 mL, 3.44 mmol ), HOBt (0.17 g, 1.29 mmol ), EDCI (0.33 g, 1.72 mmol ) and  THF 
(5 mL). The reaction mixture was stirred over night while slowly warming to room temperature. 
The reaction was quenched with H2O (2 mL) and the solvent was condensed. The residue was 
dissolved in EtOAc (30 mL) and the organic layer was washed with 1 N HCl (1 x 20 mL), 
saturated NaHCO3 solution (1 x 20 mL) and brine (1x 20 mL). Then the organic layer was dried 
over MgSO4 and concentrated at high vacuum. Chromatography (10% EtOAc-Hexane) over 
silica gel (100-200) provided compound 2a as white hygroscopic foam (Yield: 87%).  
Hydrogenolysis of benzyl ester of heterocyclic conjugated peptides 
To a stirred solution of compound 2a (0.15 g) and 10% Pd/C (10% w/w) in methanol (2.5 mL), 
ammonium formate (2 equiv) was added. The resulting reaction mixture was stirred at room 
temperature. After  the  completion  of  hydrogenolysis  (monitored  by  TLC),  the  mixture  
was  filtered   through celite and washed with methanol. The combined washings and filtrate  
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were evaporated. The residue was taken up in chloroform and washed with 50% saturated 
NaC1 solution to remove ammonium formate. The solvent was removed under reduced 
pressure and triturated with ether to obtain the hydrolyzed compound 3a (Yield: 90%).  
Analytical data of synthesized compounds 
The spectral data (H1 NMR and mass spectra) confirmed the structures of the synthesized 
compounds. The analytical data of the compounds are given below. 
 Compound 2a: Yield: 87%., 1H NMR (DMSO-D6): δ 12.16 ( s, 1H), 8.11-8.07 (t, 2H, 
J=9.0Hz), 7.77-7.75 (d, 1H, J=8.2Hz), 7.60-7.58 (d, 1H, J=8.1Hz), 7.48-7.36 (t, 1H, 
J=7.8Hz), 7.34 (s, 5H ), 5.11 (s, 2H), 4.40-4.38 (m, 1H), 4.37-4.36 (m, 1H), 3.74-3.72 (m, 
1H), 3.71 (m, 1H), 2.58-2.57 (m, 2H), 2.22-2.18 (m, 3H), 1.95-1.93 (m, 5H), 1.91-1.90 (m, 
1H),  0.87-0.84 (d, 6H, J=11.8). MS m/z: 519.2 (M+). 
 Compound 3a: Yield: 90%., 1H NMR (DMSO-D6): δ 12.18 ( s, 1H), 8.11-8.07 (t, 2H, J=9.0Hz), 
7.77-7.75  (d, 1H, J=8.2Hz), 7.60-7.58 (d, 1H, J=8.1Hz), 7.48-7.36 (t, 1H, J=7.8Hz), 4.40-4.38 (m, 
1H), 4.37-4.35 (m, 1H), 3.75-3.72 (m, 1H), 3.71-3.70 (m, 1H), 2.58-2.57 (m, 2H), 2.20-2.18 (m, 3H), 
1.95-1.94 (m, 5H), 1.91-1.90 (m, 1H),  0.86-0.84 (d, 6H, J=11.8).MS m/z: 429.3 (M+). 
 Compound 4a: Yield: 86%., 1H NMR (DMSO-D6): δ 12.16 ( s, 1H), 8.08-8.06 (d, 3H, 
J=8.0Hz), 7.77-7.75 (d, 1H, J=8.2Hz), 7.62-7.60 (d, 1H, J=8 Hz), 7.47-7.46 (t, 1H, 
J=7.4Hz), 7.34 (s, 5H ), 5.11 (s, 2H), 4.38-4.32 (m, 2H), 3.73(m, 1H), 3.72 (m, 2H), 3.71 (m, 
1H), 2.61-2.50 (m, 2H), 2.21-2.19 (m, 3H), 1.95-1.93 (m, 5H), 1.91-1.89 (m, 1H),  0.87-0.82 
(m, 6H). MS m/z: 576.2 (M+). 
 Compound 5a: Yield: 86%., 1H NMR(DMSO-D6): δ 12.17 ( s, 1H), 8.08-8.06 (d, 3H, 
J=8.0Hz), 7.77-7.75 (d, 1H, J=8.2Hz), 7.62-7.60 (d, 1H, J=8 Hz), 7.47-7.46 (t, 1H, J=7.4Hz), 
4.38-4.34 (m, 2H), 3.74(m, 1H), 3.72 (m, 2H), 3.70 (m, 1H), 2.62-2.50 (m, 2H), 2.20-2.19 (m, 
3H), 1.96-1.92 (m, 5H), 1.91-1.89 (m, 1H),  0.86-0.82 (m, 6H). MS m/z: 484.4 (M-). 
 Compound 6a: Yield: 85%., 1H NMR (DMSO-D6): δ 12.17 (s, 1H), 8.23 (s, 1H), 8.09-
8.07 (d, 1H, J= 8.4Hz ), 7.93-7.91 (d, 2H, J= 8.4Hz), 7.90-7.77 (t, 1H, J=7.6Hz), 7.75-
7.73(d, 1H, J= 8.4Hz), 7.48-7.46 (t, 1H, J=7.6Hz), 7.35 (s, 5H ), 5.11 (s, 2H), 4.36 (m, 2H), 
4.33(m, 1H), 3.75-3.73 (m, 3H), 3.72 (m, 1H), 2.85-2.84 (m, 2H), 2.25-2.24 (m, 3H),  1.97-
1.95 (m, 6H), 1.92-1.90 (m, 1H), 0.86-0.81 (m, 12H). MS m/z: 674.8 (M+). 
 Compound 7a: Yield: 86%., 1H NMR (DMSO-D6): δ 12.18 (s, 1H), 8.24 (s, 1H), 
8.09-8.07 (d, 1H, J= 8.4Hz ), 7.93-7.91 (d, 2H, J= 8.4Hz), 7.90-7.77 (t, 1H, J=7.6Hz), 
7.75-7.73(d, 1H, J= 8.4Hz), 7.48-7.46 (t, 1H, J=7.6Hz), 4.38 (m, 2H), 4.33(m, 1H), 3.74-
3.73 (m, 3H), 3.72 (m, 1H), 2.85-2.83 (m, 2H), 2.26-2.24 (m, 3H), 1.97-1.94 (m, 6H), 1.93-
1.90 (m, 1H), 0.86-0.80 (m, 12H). MS m/z: 585.2 (M+). 
 Compound 8a: Yield: 83%., 1H NMR (DMSO-D6): δ 12.19 (s, 1H), 8.24-8.22 (m, 1H), 8.11-
8.09  (m, 2H ), 7.97-7.95 (d, 1H, J=8.4Hz), 7.89-7.86 (m, 2H), 7.86-7.84 (d, 1H, J= 8.1Hz), 7.70-7.53 
(t,1H, J= 7.6Hz), 7.34 (s, 5H), 5.10 (s, 2H), 4.35-4.32 (m, 2H), 4.14 (m, 1H), 3.73-3.55 (m, 6H), 
2.71-2.65 (m, 2H), 2.24-2.21 (m, 3H), 1.98-1.87 (m, 7H), 0.84-0.80 (m, 12H). MS m/z: 731.8 (M+). 
 Compound 9a: Yield: 88%. 1H NMR (DMSO-D6): δ δ 12.20 (s, 1H), 8.25-8.22 (m, 1H), 
8.11-8.08  (m, 2H ), 7.97-7.95 (d, 1H, J=8.4Hz), 7.90-7.86 (m, 2H), 7.86-7.84 (d, 1H, J= 8.1Hz), 
7.70-7.53 (t,1H, J= 7.6Hz), 4.35-4.33 (m, 2H), 4.14-4.20 (m, 1H), 3.73-3.59 (m, 6H), 2.70-2.65 
(m, 2H), 2.24-2.22 (m, 3H), 1.98-1.87 (m, 7H), 0.85-0.80 (m, 12H). MS m/z: 642.5 (M+)  
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Antibacterial assay  
In vitro antibacterial assays were performed against Bacillus substilis, Escherichia coli, 
Pseudomonas fluorescens, Xanthomonas campestris pvs and Xanthomonas oryzae by using 
the disc diffusion method9. The bacterial strains were maintained on LB agar medium at 28 
οC. The bacteria were grown in LB broth, centrifuged at 10,000 rpm for 5 min; pellet was 
dissolved in double distilled water and used to inoculate the plates. The paper discs 
containing streptomycin and tetracyclin were used as positive control and DMSO as 
negative control. Each disc contained 10 µg of standard drugs and 10 µg synthesized 
compounds. Plates were first kept at 4 °C for 2 h to allow the diffusion of chemicals and 
then incubated at 28 °C. All the compounds were tested in triplicate and inhibition zones 
were measured in mm after 24 h of incubation. 
Table 1. Heterocyclic conjugated peptides with their analytical data. 
 
a G= Glycine, P= Proline, V= Valine 
Results and Discussion  
The biological activities of the synthesized quinazolinone conjugated peptides were tested    
against bacterial strains, Bacillus-substilis (gram positive) and Escherichia-coli, 
Pseudomonas-fluorescens, Xanthomonas-campestris pvs and  Xanthomonas-oryzae (gram 
negative) and are given in Table 2. Each fragment of these compounds i.e 4-(4-oxo-3,4- 
dihydroquinazolin-2-yl)butanoic acid, VP, GVP, VGVP and GVGVP peptides were tested  
for antibacterial activity and found inactive10. Even though the peptides chosen were less 
hydrophobic and inactive towards mentioned bacterial strains, their conjugation with 
precursor 1a showed increased antimicrobial activity (Table 2).   
 From the Table 2, it is observed that the antimicrobial activity increases with increase in 
length of peptide chain. Both benzylated and debenzylated product of quinazolinone 
conjugated peptides (2a-9a) showed parallel trends towards the antimicrobial activity with 
respect to peptide chain length. However, the debenzylated product of these molecules (3a, 
5a, 7a, 9a) showed enhanced activity than its respective counterparts (2a, 4a, 6a, 8a). It was 
observed that the quinazolinone conjugated with VGVP and GVGVP (6a, 7a, 8a, 9a) 








Values (M+) Formula 
HPLC 
RT 
2a VP-OBzl 518.25 519.2 C29H34N4O5 9.070 
3a VP-OH 428.21 429.3 C22H28N4O5 5.397 
4a GVP-OBzl 575.27 576.2 C31H37N5O6 9.086 
5a GVP-OH 485.23 484.4(M-) C24H31N5O6 5.659 
6a VGVP-OBzl 674.34 674.8 C36H46N6O7 9.125 
7a VGVP-OH 584.30 585.2 C29H40N6O7 7.038 
8a GVGVP-OBzl 731.36 731.8 C38H49N7O8 9.300 
9a GVGVP-OH 641.32 642.5 C31H43N7O8 7.072 
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 In order to correlate the appropriate structure activity relationship, the hydrophobicity of 
synthesized molecules was evaluated using RP-HPLC, C18 column surface which has affinity for 
hydrophobicity11, so more retained compound have higher hydrophobic nature. A plot of retention 
time of compounds against its antimicrobial activity (Figure 1) showed that both benzylated 
and its hydrolyzed compounds (2a - 9a) having more elongated peptide chain exhibits more   
hydrophobic  nature  and  showed  higher  antimicrobial  activities  compared  to  the compounds 
having shorter peptide chain. But hydrolyzed compounds (3a, 5a, 7a, 9a) exhibit less hydrophobic 
character compared to their counterparts (2a, 4a, 6a, 8a), still they have shown more antimicrobial 
activity. This may be due to increase in polarity of these compounds and indicates that increase in 
the polarity also has an impact on the activity12. 
Table 2. Inhibitory Zone (diameter) mm of compounds against tested bacterial strains by 
disc diffusion method. 












1a 0 0 0 0 0 
2a 6 7 5 4 6 
3a 8 10 9 7 8 
4a 10 8 9 6 5 
5a 11 10 10 13 11 
6a 18 19 18 20 17 
7a 20 23 22 23 21 
8a 21 20 24 23 26 
9a 28 24 27 28 30 
Streptomycin 17 21 23 - - 
Tetracycline - - - 19 18 
Streptomycin (10 µg/disc), Tetracycline (10 µg/disc) were used as positive control & compounds (10 µg/disc) 
a

















5 6 7 8 9 10
 
 
Figure 1. Correlation between RT and antibacterial activity. 
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 Indeed, 4-(4-oxo-3,4-dihydroquinazolin-2-yl)butanoic acid conjugated peptides (2a-9a) 
having an additional methylene group in its alkyl chain showed less hydrophobic nature and 
also showed the slightly lesser antimicrobial activities compare to that of 4-(4-oxo-3,4- 
dihydroquinazolin-2-yl)propanoic acid conjugated peptide (2-9) which has been discussed in 
our previous study7. To evaluate this, a plot of antimicrobial activities of 4-(4-oxo-3,4- 
dihydroquinazolin-2-yl)butanoic acid and 4-(4-oxo-3,4-dihydroquinazolin-2-yl)propanoic 
acid conjugated peptides against their retention times is presented in Table 2. From the 
Figure 2, it is evident that the increase in the length of carbon chain in quinazolinone 
precursors has little / no impact on the activity of the molecules. Both the set of molecules 
(2 - 9 and 2a - 9a) showed similar and steady increase in activity as peptide chain length and 
hydrophobicity (HPLC-RT) increases. 
 
 
Figure 2. RT & microbial activity of B. subtilis. 
 Further it is evident that activity towards gram -ve bacteria is more compared to the 
gram +ve. This may be due to the distance between the charged groups and the heterocyclic 
ring. Another widely postulated mechanism is that of the "self-promoted uptake" of the 
peptides across the outer membranes of gram negative bacteria which consists 
lipopolysaccaride surface13. This suggest that the peptides interact with the negatively 
charged outer membrane and subsequent channel formation in the cytoplasmic membrane 
via either "barrel-stave" or a" carpet" mechanism resulting in cell death14. 
Conclusion  
Following our ongoing investigations on development of quinazolinone conjugated peptides 
as  novel  antimicrobial  agents, in  the present study, by  enhancing the alkyl chain length in  
Compound 
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the quinazolinone showed similar activities but fairly less compare to quinazolinone of 
shorter alkyl chain length. Thus, the increase in the length of carbon chain in quinazolinone 
precursors may have little / no impact on the activity of the molecules. But the length of  
peptide chain, hydrophobicity and variation in polarity of these molecules play important 
role in their antimicrobial activities. It was noticed that quinazolinone conjugated VGVP and 
GVGVP peptides showed increased activity by nearly two fold compared to conventional 
antimicrobials.  
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